Manila Times Business
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs”, Stock Code: 9887.HK) today announced updated first‑in‑human clinical data for LBL‑034, its GPRC5D/CD3 bispecific T‑cell engager (TCE). The updated results were delivered in an oral presentation at the 2026 Annual Meeting of the European Soc
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Flights resume at Riyadh airport as Houthis attack Saudi
Just now
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Just now
Madrid festival reroutes thousands of sheep to avoid housing protest camp
1h ago
Meshy Expands Access to AI-Powered 3D Creation With Free Browser-Based Tools
1h ago